Brenda Cooperstone Buys Shares of Lexeo Therapeutics
Lexeo Therapeutics sees insider buying as Brenda Cooperstone acquires 35,000 shares.
Key Points
- Brenda Cooperstone bought 35,000 shares of Lexeo Therapeutics, Inc. on June 25, 2026, as part of insider buying activity.
- Lexeo Therapeutics, trading near $4.75, has a market cap of $373 million and a beta of 1.389.
- Institutional investors like Paradigm Biocapital Advisors and BlackRock have also adjusted their positions in Lexeo.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Brenda Cooperstone, an insider at Lexeo Therapeutics, Inc. (NasdaqGM: LXEO), purchased 35,000 shares of the company on June 25, 2026. This transaction reflects insider buying activity, potentially signaling confidence in the company's future.
Other Institutional Activity in Lexeo Therapeutics
Several institutional investors have recently adjusted their positions in Lexeo Therapeutics. Paradigm Biocapital Advisors LP significantly increased its holdings by 1,420,936 shares, ending with 6,184,134 shares valued at about $35.5 million. BlackRock, Inc. also boosted its position by 203,308 shares, holding a total of 5,110,871 shares worth approximately $29.3 million. Affinity Asset Advisors, LLC saw a substantial increase of 1,850,211 shares, bringing its total to 5,050,211 shares valued at nearly $28.9 million. On the other hand, Janus Henderson Group PLC reduced its stake by 533,206 shares, leaving it with 4,976,429 shares valued at about $28.5 million.
Lexeo Therapeutics, Inc. Stock Down 1.0%
Shares of Lexeo Therapeutics traded near $4.75 on Tuesday. The company, with a market capitalization of $373 million, operates in the biotechnology sector. Lexeo has a forward P/E ratio of -3.82, indicating it is not currently profitable, and a beta of 1.389, suggesting higher volatility compared to the market. The stock's 52-week range spans from $3.60 to $10.99, with a 50-day moving average of $5.27 and a 200-day moving average of $7.14. The company maintains a strong liquidity position with a current ratio of 14.156 and a quick ratio of 13.605.
$LXEO stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Lexeo Therapeutics, Inc.
On June 25, 2026, several insiders, including Brenda Cooperstone, Timothy Van Hauwermeiren, Steven Altschuler, Mette Kirstine Agger, Tolga Tanguler, and Reinaldo Diaz, each bought 35,000 shares of Lexeo Therapeutics. These transactions were not part of a pre-planned trading program, indicating active insider interest.
Analysts Set New Price Targets
Analysts have been active in setting new price targets for Lexeo Therapeutics. On June 25, 2026, JP Morgan maintained its 'buy' rating with a target price of $9.0. Previously, Chardan Capital reiterated a 'buy' rating with a $17.0 target on May 11, 2026. The consensus among analysts is a 'strong buy,' with a mean target price of $20.6.
About Lexeo Therapeutics
Lexeo Therapeutics, Inc. is a biotechnology company based in New York, focusing on genetic medicine for hereditary and acquired diseases. The company's pipeline includes gene therapy candidates targeting conditions like Friedreich ataxia cardiomyopathy and Alzheimer's disease. Founded in 2017, Lexeo collaborates with institutions like Cornell University to advance its clinical trials and research.
Bottom Line
Brenda Cooperstone's recent purchase of Lexeo Therapeutics shares is a notable insider transaction, potentially reflecting confidence in the company's prospects. With institutional investors also adjusting their stakes, Lexeo remains a company to watch in the biotechnology sector. Investors should remember that insider transactions and institutional filings are backward-looking and may not indicate current positions.
Get Lexeo Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $LXEO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.